Robert B. Huizinga

1.5k total citations · 1 hit paper
33 papers, 709 citations indexed

About

Robert B. Huizinga is a scholar working on Rheumatology, Transplantation and Hepatology. According to data from OpenAlex, Robert B. Huizinga has authored 33 papers receiving a total of 709 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Rheumatology, 14 papers in Transplantation and 10 papers in Hepatology. Recurrent topics in Robert B. Huizinga's work include Systemic Lupus Erythematosus Research (17 papers), Renal Transplantation Outcomes and Treatments (14 papers) and Hepatitis C virus research (8 papers). Robert B. Huizinga is often cited by papers focused on Systemic Lupus Erythematosus Research (17 papers), Renal Transplantation Outcomes and Treatments (14 papers) and Hepatitis C virus research (8 papers). Robert B. Huizinga collaborates with scholars based in United States, Canada and Netherlands. Robert B. Huizinga's co-authors include Laura Lisk, Neil Solomons, Samir V. Parikh, Simrat Randhawa, Cristina Arriens, Y K Onno Teng, Dawn J. Caster, Ellen M. Ginzler, Keisha L. Gibson and Brad H. Rovin and has published in prestigious journals such as The Lancet, PLoS ONE and Endocrinology.

In The Last Decade

Robert B. Huizinga

27 papers receiving 678 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

2021 299 citations Brad H. Rovin, Y K Onno Teng et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert B. Huizinga United States	12	461	245	210	144	114	33	709
Louise Oni United Kingdom	15	245 0.5×	210 0.9×	297 1.4×	25 0.2×	9 0.1×	46	641
Yohan Duny France	15	117 0.3×	49 0.2×	107 0.5×	207 1.4×	74 0.6×	20	763
Smaragdi Marinaki Greece	12	94 0.2×	86 0.4×	108 0.5×	67 0.5×	33 0.3×	53	462
Carlos Chiurchiu Argentina	13	63 0.1×	126 0.5×	629 3.0×	26 0.2×	121 1.1×	39	958
Giuseppe Picciotto Italy	13	36 0.1×	66 0.3×	224 1.1×	45 0.3×	37 0.3×	30	485
Jonathan J. Hogan United States	14	84 0.2×	59 0.2×	251 1.2×	22 0.2×	33 0.3×	31	556
P Errasti Spain	14	33 0.1×	113 0.5×	106 0.5×	34 0.2×	273 2.4×	54	614
Meritxell Ibernón Spain	20	39 0.1×	136 0.6×	333 1.6×	68 0.5×	631 5.5×	39	1.1k
Sumio Tateno Japan	12	129 0.3×	60 0.2×	516 2.5×	16 0.1×	15 0.1×	25	628
S. Mulgaonkar United States	15	52 0.1×	113 0.5×	87 0.4×	27 0.2×	615 5.4×	37	924

Countries citing papers authored by Robert B. Huizinga

Since Specialization

Citations

This map shows the geographic impact of Robert B. Huizinga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert B. Huizinga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert B. Huizinga more than expected).

Fields of papers citing papers by Robert B. Huizinga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert B. Huizinga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert B. Huizinga. The network helps show where Robert B. Huizinga may publish in the future.

Co-authorship network of co-authors of Robert B. Huizinga

This figure shows the co-authorship network connecting the top 25 collaborators of Robert B. Huizinga. A scholar is included among the top collaborators of Robert B. Huizinga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert B. Huizinga. Robert B. Huizinga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jozic, Ivan, et al.. (2026). Wound Healing Property of a Novel Thermo‐Reversible Wound Gel With Lasting Antimicrobial and Antibiofilm Activity. International Wound Journal. 23(2). e70845–e70845.

Rovin, Brad H., Clarissa A. Cassol, Samir V. Parikh, et al.. (2025). Effect of Long‐Term Voclosporin Treatment on Renal Histology in Patients With Active Lupus Nephritis With Repeat Renal Biopsies. Arthritis & Rheumatology. 77(10). 1387–1393.

Palmer, Biff F., et al.. (2025). The kidney injury biomarker profile of patients with lupus nephritis remains unchanged with the second-generation calcineurin inhibitor voclosporin. PubMed. 5. 1540471–1540471.

Kaplan, Jeffrey B., et al.. (2025). Synergistic activity of dispersin B and benzoyl peroxide against Cutibacterium acnes/Staphylococcus epidermidis dual-species biofilms. PLoS ONE. 20(3). e0320662–e0320662. 1 indexed citations

Mariani, Laura, Howard Trachtman, Aliza Thompson, et al.. (2024). Proteinuria as an End Point in Clinical Trials of Focal Segmental Glomerulosclerosis. American Journal of Kidney Diseases. 85(5). 610–617. 1 indexed citations

Saxena, Amit, Ellen M. Ginzler, Keisha L. Gibson, et al.. (2023). Safety and Efficacy of Long‐Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial. Arthritis & Rheumatology. 76(1). 59–67. 49 indexed citations

Gelder, Teun van, Edgar V. Lerma, Kory J. Engelke, & Robert B. Huizinga. (2022). Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis. Expert Review of Clinical Pharmacology. 15(5). 515–529. 36 indexed citations

Rehaume, Linda M., et al.. (2021). Chronic Dosing of Voclosporin at Clinically Relevant Exposure Levels Does Not Induce Renal Fibrosis Markers in Rats. Journal of the American Society of Nephrology. 32(10S). 621–621.

Rovin, Brad H., Y K Onno Teng, Ellen M. Ginzler, et al.. (2021). Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet. 397(10289). 2070–2080. 299 indexed citations breakdown →

10.

Kolic, Jelena, Haoning Howard Cen, Evgeniy Panzhinskiy, et al.. (2020). Differential Effects of Voclosporin and Tacrolimus on Insulin Secretion From Human Islets. Endocrinology. 161(11). 22 indexed citations

11.

Huizinga, Robert B., et al.. (2020). Organizational Metaphors.

12.

Dobronravov, Vladimir, MA Dooley, И. Э. Адзерихо, et al.. (2017). LB0002 48 week complete remission of active lupus nephritis with voclosporin. Annals of the Rheumatic Diseases. 76. 153–153. 7 indexed citations

13.

Huizinga, Robert B., et al.. (2017). 20 Aurion study: 24-week data of multi-target therapy with voclosporin, mmf and steroids for active lupus nephritis. A10.3–A11. 2 indexed citations

14.

Huizinga, Robert B., Neil Solomons, & Mark D. Abel. (2016). SP671CALCINEURIN INHIBITION WITHOUT THERAPEUTIC DRUG MONITORING?. Nephrology Dialysis Transplantation. 31(suppl_1). i318–i319. 1 indexed citations

15.

Huizinga, Robert B., et al.. (2013). Pharmacokinetics of voclosporin in renal impairment and hepatic impairment. The Journal of Clinical Pharmacology. 53(12). 1303–1312. 11 indexed citations

16.

Busque, Stéphan, Marcelo Cantarovich, S. Mulgaonkar, et al.. (2011). The PROMISE Study: A Phase 2b Multicenter Study of Voclosporin (ISA247) Versus Tacrolimus in De Novo Kidney Transplantation. American Journal of Transplantation. 11(12). 2675–2684. 58 indexed citations

17.

Papp, Kim, Robert Bissonnette, Norman Wasel, et al.. (2008). Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. The Lancet. 371(9621). 1337–1342. 61 indexed citations

18.

Papp, Kim, Neil H. Shear, Robert B. Huizinga, & Walter P. Maksymowych. (2008). Voclosporin (ISA247) for plaque psoriasis – Authors' reply. The Lancet. 372(9642). 889–889. 1 indexed citations

19.

Gupta, Aditya K., Richard G. Langley, Charles Lynde, et al.. (2008). ISA247: Quality of Life Results from a Phase II, Randomized, Placebo-Controlled Study. Journal of Cutaneous Medicine and Surgery. 12(6). 268–275. 12 indexed citations

20.

Bissonnette, Robert, Kim Papp, Yves Poulin, et al.. (2006). A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. Journal of the American Academy of Dermatology. 54(3). 472–478. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact